骨髓增生异常综合征合并冠心病与特定体细胞突变及并发心血管疾病风险的关系OA

Objective:To explore the relationship between myelodysplastic syndrome(MDS)complicated with coronary heart disease(CHD)and specific somatic mutations,and the risk of concurrent cardiovascular disease.Meth-ods:A retrospective review of medical records was conducted for 160 patients with MDS.Patients were followed until the occurrence of an endpoint event or August 31,2025.Based on the presence of concomitant CHD,they were divid-ed into a CHD group(n=44)and a control group(n=116).Multivariate Logistic regression was used to analyze the relationship between SF3B1/TP53 co-mutation and CHD,and sensitivity analysis was used to test the robustness of the results.The Fine-Gray competitive risk model was used to analyze the association of CHD and SF3B1/TP53 co-mutation with new-onset cardiovascular disease.Results:Compared with the control group,SF3B1/TP53 co-muta-tions accounted for more in the CHD group,and the difference was still statistically significant after FDR correction(P＜0.05).In the multivariate Logistic regression analysis of the association between SF3B1/TP53 co-mutation and CHD in MDS patients,it was found in model 1 that SF3B1 with TP53 mutation was associated with CHD in MDS patients(P＜0.05);in model 2,after adjusting for more confounding factors,SF3B1 with TP53 mutation was still strongly associated withCHD in MDS patients(P＜0.05).In the analysis of the Fine-Gray competitive risk model,it was found that the risk of new cardiovascular disease in MDS patients with CHD was higher than that in patients without CHD(P＜0.05).Conclusion:SF3B1/TP53 co-mutation is related to the occurrence of CHD in MDS patients.MDS patients with CHD complications have a higher risk of new cardiovascular diseases.